News

CMN Weekly (5 November 2021) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Karen O'Hanlon Cohrt - Nov. 5, 2021

Top Picks

  • Tessera Therapeutics has announced a research and development collaboration with the Cystic Fibrosis (CF) Foundation, that will involve the use of Tessera’s Gene Writing technology to make true corrections of specific CF mutations, such as the F508-del mutation, which drives roughly 70% of CF cases, as well as other nonsense mutations, and to introduce a functional full-length copy of the CFTR gene at its endogenous locus.
  • Researchers in San Francisco have demonstrated that engineered bacteriophage M13 can be used to deliver CRISPR-Cas9 cargo to Escherichia coli within the mouse gastrointestinal tract, and propose a robust and experimentally tractable platform for strain-specific depletion and manipulation of the gut microbiome. The findings were published in Cell Reports this week.

To continue reading about...

  • Industry
  • American Society of Hematology Annual meeting
  • Research
  • COVID-19
  • 3rd Quarter company financial reports

Sign up to our free weekly CMN Weekly Newsletter here

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (5 November 2021) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
Sickle Cell Disease, SCD
Sponsors:
Beam Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Hereditary Angioedema, HAE (NCT05120830)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukemia, AML, (NCT05066165)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine